Navigation Links
Research-based Pharmaceutical Industry Calls for Public-Private Sector Engagement to Accelerate Progress Towards the Millennium Development Goals (MDGs) and in Planning New Development Agenda
Date:9/23/2013

NEW YORK, September 23, 2013 /PRNewswire/ --


  • Since the MDGs' launch, many notable health successes resulted from coordinated actions by many contributors from public and private sectors and civil society.
  • Pharmaceutical companies lead over 220 partnerships to strengthen health systems and improve peoples' health in low- and middle-income countries.
  • Research-based pharmaceutical industry's contributions to improving health demonstrate its unique role as partner in post-2015 development agenda.

As governments gather in New York this week to review the world's efforts for the achievement of the United Nations Millennium Development Goals (MDGs) and chart the new pathway for global development beyond 2015, leaders of the research-based pharmaceutical industry call for continued dialogue and constructive engagement involving all stakeholders.

With more than 220 global partnerships addressing a wide range of diseases and focusing on prevention, improvements in health system infrastructures, training, pharmaceutical R&D, and medicine and vaccine donations, the industry plays an important role in advancing progress toward the health-related MDGs. A new publication launched today by IFPMA shows that transformative partnerships and accountability frameworks between civil society, the private sector, and governments can promote more equitable, inclusive and sustainable development.

Eduardo Pisani, IFPMA Director General, says, "The United Nations calls for the 'engagement of responsible business and civil society' and recognizes the 'need to pool efforts as never before.'[1] This call for action resonates strongly with the research-based pharmaceutical industry - where expanding access to healthcare and meeting unmet medical needs are at the very core of our daily operations."

While the world should not lose sight of the unfinished business in the current health-related MDGs, emerging issues such as diabetes, cancer, respiratory and cardiovascular diseases, will increasingly challenge health systems worldwide in the next fifteen years. Eighty (80) percent of deaths due to these 'non-communicable' diseases occur in low- and middle-income countries and will inevitably increase pressure to find cost-effective interventions to prevent or treat diseases.

"To maximize the impact of private sector action on global health goals, we need proactive, cross-sector engagement in framing the next set of development goals," says Eduardo Pisani. "The original MDGs were conceived without a clear map as to how the private sector could contribute. Pharmaceutical companies came to the fore anyway-recognizing the criticality of their unique contributions. But we know that there is no sector-not government, not civil society, not industry-that can alone drive the system-wide change that is required to address the most intractable health challenges."

Related materials:

OpEd: Meeting global development goals requires more cross-sector partnerships, by Eduardo Pisani, IFPMA Director General and Aron Cramer, CEO, Business for Social Responsibility (BSR)

--------------------------------------------------

1. United Nations, A life of dignity for all: accelerating progress towards the Millennium Development Goals and advancing the United Nations development agenda beyond 2015, Report of the Secretary-General.

IFPMA publication: Sustainable Health and Multi-stakeholder Action - Lessons Learned from the MDGs)


'/>"/>
SOURCE International Federation of Pharmaceutical Manufacturers and Associations
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Research-based Pharmaceutical Industry Launches Do You Mind? Campaign to Fight Mental and Neurological Disorders
2. Research-based Pharmaceutical Industry and International Federation of Red Cross and Red Crescent Societies Join Forces to Prevent Non-Communicable Diseases
3. Boehringer Ingelheim Pharmaceuticals, Inc. colabora con Univision Communications Inc. para lanzar una campaña integrada en español
4. Boehringer Ingelheim Pharmaceuticals, Inc. Collaborates With Univision Communications Inc. To Launch An Integrated Campaign In Spanish
5. Par Pharmaceutical Begins Shipment of KHEDEZLA (desvenlafaxine) Extended-release Tablets, 50 mg and 100 mg
6. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
7. Immune Pharmaceuticals Inc. Trading Symbol is Now IMNP on Both NASDAQ OMX Stockholm Exchange and OTCQX Trading Platform
8. Isis Pharmaceuticals to Conduct Webcast and Conference Call to Discuss ISIS-APOCIII Rx Phase 2 Data
9. Harwood Feffer LLP Announces Investigation of Transcept Pharmaceuticals, Inc.
10. New Pharmaceutical Product Launch Spend: Developing Competitive Launch and Pre-launch Budgets to Ensure a Successful Market Entry
11. Avanir Pharmaceuticals Announces Publication of AVP-825 Pharmacokinetic Data in Journal "Headache"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ZirMed Inc ., a recognized leader in cloud-based revenue cycle ... ranked #1 by its users for the seventh consecutive year ... ZirMed was recognized as the top-ranked end-to-end revenue cycle management ... 200 beds and holds one of the longest #1 ranking ... ...
(Date:9/13/2017)... OrthoAtlanta has been named the official orthopedic and sports ... the 2018 College Football Playoff (CFP) National Championship to be ... Atlanta, Georgia . OrthoAtlanta is proud to ... in many activities leading up to, and including the national ... OrthoAtlanta ...
(Date:9/12/2017)... SAN FRANCISCO , Sept. 12, 2017 /PRNewswire/ ... Lifecycle Management Solutions (VLMS), is pleased to announce ... as a member of its Board of Directors ... 2017. ValGenesis VLMS enables life science companies to ... eliminate the use of paper in this process. ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... ... treating sleep apnea using cutting-edge Oventus O2Vent technology. As many as ... disorder characterized by frequent cessation in breathing. Oral appliances can offer significant relief ...
(Date:10/12/2017)... ... 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the ... new design of the shoulder pad. The shoulder pad provides optimal support and ... pain while using cold therapy. By utilizing ice and water that is circulated from ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about ... intend to develop to enable prevention of a major side effect of chemotherapy ... especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... Leading pediatric ... peers in Washington, D.C., for the 49th Congress of the International Society of ... Vice President of the Center for Cancer and Blood Disorders at Children’s ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... nation's first interactive health literacy software tool, and the Cancer Patient Education Network ... cancer patient education, today announce a new strategic alliance. , As CPEN’s ...
Breaking Medicine News(10 mins):